The EVERY Company Further Expands its IP Estate with European Union Patent for Recombinant Ovalbumin
SAN FRANCISCO–(BUSINESS WIRE)–The EVERY Company (“EVERY”), a leader in crafting highly functional protein ingredients, has been granted yet another seminal patent for its recombinant Ovalbumin ingredient, expanding its coverage to the European Union. EVERY’s European patent comes on the heels of the Company’s announcement of its pioneering US patent, US 12,096,784, and further builds on EVERY’s […]